



December 28, 2016  
Announcement no. 27

### **BioPorto expands its NGAL related patent portfolio**

---

Today, BioPorto has entered into an exclusive license agreement with The Trustees of Columbia, University for NGAL patents. The Agreement covers several world-wide NGAL patents and applications, with the right to sublicense these patents.

These additional NGAL patents will strengthen BioPorto's existing NGAL patent portfolio.

Peter Mørch Eriksen, CEO of BioPorto, comments: "I am very excited about this license agreement. Not only will these additional patents enhance the position of our NGAL product and partnerships with diagnostic companies but they allow us to continue to establish NGAL globally as an important biomarker for acute kidney injury".

#### **For further information, please contact:**

Peter Mørch Eriksen, CEO  
Gry Husby Larsen, General Counsel  
Telephone +45 4529 0000, e-mail [investor@bioporto.com](mailto:investor@bioporto.com)

#### *About BioPorto*

*BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.*